Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Tilorone dihydrochloride (tilorone) is a small-molecule, orally bioavailable drug that is used clinically as an antiviral outside the United States. A machine-learning model trained on anti-Ebola virus (EBOV) screening data previously identified tilorone as a potent in vitro EBOV inhibitor, making it a candidate for the treatment of Ebola virus disease (EVD). In the present study, a series of in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) assays demonstrated the drug has excellent solubility, high Caco-2 permeability, was not a P-glycoprotein substrate, and had no inhibitory activity against five human CYP450 enzymes (3A4, 2D6, 2C19, 2C9, and 1A2). Tilorone was shown to have 52% human plasma protein binding with excellent plasma stability and a mouse liver microsome half-life of 48 min. Dose range-finding studies in mice demonstrated a maximum tolerated single dose of 100 mg/kg of body weight. A pharmacokinetics study in mice at 2- and 10-mg/kg dose levels showed that the drug is rapidly absorbed, has dose-dependent increases in maximum concentration of unbound drug in plasma and areas under the concentration-time curve, and has a half-life of approximately 18 h in both males and females, although the exposure was ∼2.5-fold higher in male mice. Tilorone doses of 25 and 50 mg/kg proved efficacious in protecting 90% of mice from a lethal challenge with mouse-adapted with once-daily intraperitoneal (i.p.) dosing for 8 days. A subsequent study showed that 30 mg/kg/day of tilorone given i.p. starting 2 or 24 h postchallenge and continuing through day 7 postinfection was fully protective, indicating promising activity for the treatment of EVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×
“A significant percentage of drug candidate attrition can be attributed to problems that arise from pharmacokinetic (PK) processes (38, 39).”
BackgroundWu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 2×
“In this study, we have shown that tilorone exhibits excellent drug-like properties (solubility, Caco-2 permeability, metabolic stability, and CYP inhibition) and can be labeled as a class 1 drug based on the Biopharmaceutics Classification System (54, 55).”
BackgroundEmeny, J. M., & Morgan, M. J. (1979) · Journal of General Virology · doi:10.1099/0022-1317-43-1-247 · Cited by 440
Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets
Clark, A. M., Dole, K., Coulon-Spektor, A., McNutt, A., Grass, G., Freundlich, J. S., Reynolds, R. C., & Ekins, S. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00143 · Cited by 114 · cited 1×
“While many of these properties can be reliably predicted (40, 41), there is still tremendous value to generating in vitro data for drug candidates.”
BackgroundSelf-citationMachine learning models identify molecules active against the Ebola virus in vitro
Ekins, S., Freundlich, J. S., Clark, A. M., Anantpadma, M., Davey, R. A., & Madrid, P. (2015) · F1000Research · doi:10.12688/f1000research.7217.1 · Cited by 84
Self-citation
Cited by
The natural product eugenol is an inhibitor of the ebola virus in vitro
Lane, T., Anantpadma, M., Freundlich, J. S., Davey, R. A., Madrid, P. B., & Ekins, S. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2629-0 · Cited by 88
Self-citationEbola Virus Bayesian Machine Learning Models Enable New in Vitro Leads
Anantpadma, M., Lane, T., Zorn, K. M., Lingerfelt, M. A., Clark, A. M., Freundlich, J. S., Davey, R. A., Madrid, P. B., & Ekins, S. (2019) · ACS Omega · doi:10.1021/acsomega.8b02948 · Cited by 54
Self-citationComputer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors
Capuzzi, S. J., Sun, W., Muratov, E. N., Martínez-Romero, C., He, S., Zhu, W., Li, H., Tawa, G., Fisher, E. G., Xu, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00035 · Cited by 35
Metadata
- Authors
- Ekins, S., Lingerfelt, M. A., Comer, J. E., Freiberg, A. N., Mirsalis, J. C., O'Loughlin, K., Harutyunyan, A., McFarlane, C., Green, C. E., & Madrid, P. B.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-02
- Volume
- 62
- Issue
- 2
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2768755579
- Cited by
- 65
- References
- 5
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection. https://app.cochat.ai/papers/10.1128/aac.01711-17
- The paper
- Ekins, S., Lingerfelt, M. A., Comer, J. E., Freiberg, A. N., Mirsalis, J. C., O'Loughlin, K., Harutyunyan, A., McFarlane, C., Green, C. E., & Madrid, P. B. (2018). Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01711-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.